Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02889900
Title Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca

ovary serous adenocarcinoma

peritoneal carcinoma

fallopian tube carcinoma

ovarian clear cell carcinoma

endometrioid ovary carcinoma


Cediranib + Olaparib

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.